Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 68-year-old man comes to the clinic for a 1-week follow-up after an adjustment to his heart failure medications. He has a history of ischemic cardiomyopathy with a left ventricular ejection fraction of 25%. One week ago, spironolactone 25 mg daily was added to his guideline-directed medical therapy regimen to further reduce morbidity and mortality. He is also taking sacubitril-valsartan, carvedilol, and dapagliflozin. The patient reports feeling well and has no shortness of breath, orthopnea, or lower extremity edema. His blood pressure is 114/72 mm Hg, and his pulse is 62/min. Physical examination reveals clear lungs and no jugular venous distention. Laboratory studies obtained today, compared to his baseline from one week ago, are shown in the table below:

Laboratory Parameter1 Week Ago (Baseline)Today
Serum sodium139 mEq/L138 mEq/L
Serum potassium4.4 mEq/L5.3 mEq/L
Blood urea nitrogen18 mg/dL22 mg/dL
Serum creatinine1.1 mg/dL1.3 mg/dL

Which of the following is the most appropriate next step in the monitoring and treatment evaluation of this patient?

  1. Continue the current medication regimen and repeat the basic metabolic panel in 4 weeksAnswer
  2. B
    Discontinue spironolactone and repeat the basic metabolic panel in 1 week
  3. C
    Order a renal duplex ultrasound to evaluate for bilateral renal artery stenosis
  4. D
    Refer the patient to the emergency department for intravenous calcium gluconate
  5. E
    Prescribe oral sodium polystyrene sulfonate to acutely lower the serum potassium

Answer

Continue the current medication regimen and repeat the basic metabolic panel in 4 weeks
The correct answer is to continue the current medication regimen and repeat the basic metabolic panel in 4 weeks. This patient recently started spironolactone, a mineralocorticoid receptor antagonist (MRA). MRAs, along with other renin-angiotensin-aldosterone system (RAAS) inhibitors, commonly cause a mild increase in serum potassium and serum creatinine due to alterations in intraglomerular hemodynamics. According to current heart failure guidelines, an increase in serum creatinine of up to 30% from baseline and a rise in serum potassium up to 5.5 mEq/L are considered normal, acceptable physiological responses. This patient's creatinine increased by approximately 18% (from 1.1 to 1.3 mg/dL), and his potassium is 5.3 mEq/L. Since both parameters remain safely below the threshold for concern, the MRA should be continued at the current dose. The standard monitoring protocol for MRA initiation involves checking renal function and electrolytes at 1 week, 4 weeks, and then periodically. Therefore, the most appropriate next step is to maintain therapy and recheck the labs in 4 weeks.

Step-by-Step Solution

1
Evaluate the patient's clinical status and laboratory trends following the initiation of the mineralocorticoid receptor antagonist (spironolactone).
The patient remains asymptomatic. Serum potassium increased to 5.3 mEq/L, and serum creatinine increased from 1.1 to 1.3 mg/dL (an 18% increase).
To determine if the hemodynamic and electrolyte changes are within expected physiological limits for RAAS inhibition.
2
Compare the laboratory results against guideline-established safety thresholds.
The potassium level is below the 5.5 mEq/L threshold, and the creatinine increase is below the 30% threshold.
Changes within these limits are considered normal intraglomerular hemodynamic responses that do not warrant drug discontinuation.
3
Determine the appropriate guideline-directed monitoring interval.
Continue the current dose and schedule the next laboratory check in 4 weeks.
Because the laboratory changes represent an acceptable response without crossing toxicity thresholds, the medication should be continued to maintain its mortality benefit, with the next standard monitoring check at 4 weeks.

Key Concept

After initiating RAAS inhibitors or mineralocorticoid receptor antagonists in heart failure, an increase in serum creatinine up to 30% from baseline and a rise in serum potassium up to 5.5 mEq/L are expected physiologic responses that do not require drug discontinuation.
Estimated Time:1m 15s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic